|
A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation. |
|
|
Research Funding - Novartis (Inst) |
|
|
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - bioTheranostics; Genentech; Novartis; Pfizer; Spectrum Pharmaceuticals |
|
|
Employment - Amgen; Novartis |
Stock and Other Ownership Interests - Amarin Corporation; Amgen; Cara Therapeutics; Google; Novartis; Oncothyreon |